A detailed history of Dafna Capital Management LLC transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 227,906 shares of EWTX stock, worth $7.17 Million. This represents 1.56% of its overall portfolio holdings.

Number of Shares
227,906
Previous 290,197 21.47%
Holding current value
$7.17 Million
Previous $5.23 Million 16.38%
% of portfolio
1.56%
Previous 1.34%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.88 - $29.5 $989,181 - $1.84 Million
-62,291 Reduced 21.47%
227,906 $6.08 Million
Q2 2024

Aug 14, 2024

SELL
$15.08 - $21.23 $241,280 - $339,680
-16,000 Reduced 5.23%
290,197 $5.23 Million
Q1 2024

May 15, 2024

SELL
$9.25 - $19.97 $1.32 Million - $2.86 Million
-143,187 Reduced 31.86%
306,197 $5.59 Million
Q4 2023

Feb 14, 2024

SELL
$5.51 - $12.1 $385,700 - $847,000
-70,000 Reduced 13.48%
449,384 $4.92 Million
Q2 2023

Aug 14, 2023

SELL
$5.71 - $10.29 $1.22 Million - $2.2 Million
-213,855 Reduced 29.17%
519,384 $4.03 Million
Q1 2023

May 15, 2023

SELL
$6.66 - $11.33 $223,802 - $380,733
-33,604 Reduced 4.38%
733,239 $4.89 Million
Q4 2022

Feb 14, 2023

SELL
$7.58 - $11.08 $108,159 - $158,100
-14,269 Reduced 1.83%
766,843 $6.86 Million
Q3 2022

Nov 14, 2022

BUY
$8.08 - $13.58 $688,036 - $1.16 Million
85,153 Added 12.24%
781,112 $7.69 Million
Q2 2022

Aug 15, 2022

BUY
$5.67 - $9.87 $1.92 Million - $3.35 Million
339,209 Added 95.08%
695,959 $5.54 Million
Q1 2022

May 16, 2022

BUY
$9.1 - $18.97 $3.25 Million - $6.77 Million
356,750 New
356,750 $3.46 Million

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.99B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.